EP1222202A2 - Mutants de la sous-unite b de la toxine ab 5? aux caracteristiques de conjugaison chimique modifiees - Google Patents

Mutants de la sous-unite b de la toxine ab 5? aux caracteristiques de conjugaison chimique modifiees

Info

Publication number
EP1222202A2
EP1222202A2 EP00968795A EP00968795A EP1222202A2 EP 1222202 A2 EP1222202 A2 EP 1222202A2 EP 00968795 A EP00968795 A EP 00968795A EP 00968795 A EP00968795 A EP 00968795A EP 1222202 A2 EP1222202 A2 EP 1222202A2
Authority
EP
European Patent Office
Prior art keywords
protein
subunit
toxin
amino acid
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00968795A
Other languages
German (de)
English (en)
Inventor
Harold H. Handley
Tapio Haaparanta
Karla L. Ewalt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBL Vaccin AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of EP1222202A2 publication Critical patent/EP1222202A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • This invention relates to methods of creating mutants in AB5 toxin B subunit proteins, such as cholera toxin B subunit (CTB), with altered chemical conjugation characteristics.
  • Compositions comprising the mutant AB5 toxin B subunit proteins are also discussed. Further, use of these compositions as vaccines and bioactive molecule delivery agents is also discussed.
  • Vaccines may have to be administered at a mucosal site, for example by oral or nasal delivery, in order to induce mucosal immune responses. Indeed, this may be a prerequisite for the production of vaccines against certain pathogens for which no vaccine is currently available (e.g., respiratory syncytial virus and even possibly HIV).
  • mucosal vaccines An additional potential advantage of mucosal vaccines is that they would be easier to deliver, an extremely important consideration in mass immunization programs.
  • delivery of many antigens via mucosal routes is often characterized by low immune responsiveness, due in part to inefficient uptake of antigen.
  • various strategies for effective delivery of antigens by mucosal routes have been investigated.
  • Antigens that are successfully delivered across the barrier of epithelial cells lining mucosal tracts stimulate underlying inductive sites of the mucosa-associated lymphoid tissue (MALT).
  • MALT mucosa-associated lymphoid tissue
  • Antigen-specific lymphocytes that are sensitized in the MALT migrate through the circulatory system to populate distant mucosal sites, thus mucosal immunization may provide both local and systemic protection.
  • CT Cholera toxin
  • CTB cholera toxin B protein
  • CT Vibrio cholerae enterotoxin
  • CTB Upon binding, CTB forms a planar ring structure on the membrane surface which possesses a highly polar central pore that interacts intimately with the A subunit of CT.
  • the A subunit is composed of a toxic CTA1 subunit linked to the CTA2 subunit by a disulfide bond. Liberation of CTA1 by reduction of this disulfide linkage occurs during transcytosis through the cell to its basolateral membrane. This leads to permanent activation of adenylate cyclase and ribosylation of the GTP-binding regulatory protein Gg ⁇ . These events result in the activation of sodium pumps via cAMP-dependent protein kinases and subsequent expulsion of sodium and water into the intestinal lumen.
  • CTB is clearly responsible for toxin binding to ganglioside GM-1 receptors, an essential step in cholera toxicity, the mechanism for transport of CTA1 into the cytoplasmic compartment of target cells, remains unclear.
  • Studies of CT-membrane interactions have shown that CTB binding to GM-1 incorporated into Iipid bilayers induces the formation of membrane channels.
  • bacterial enterotoxins such as cholera toxin (CT) from Vibrio cholera and the related E. coli heat-labile enterotoxin (LT), which are highly immunogenic when delivered mucosally and which can act as carriers to potentiate responses to non-related antigens.
  • CT cholera toxin
  • LT heat-labile enterotoxin
  • Both biotoxins are composed of an ADP-ribosylating A subunit which mediates toxicity, linked to a cyclic pentamer of B subunits which interacts specifically with monosialoganglioside (GM-1 ) sugars expressed on eukaryotic cells.
  • GM-1 monosialoganglioside
  • the function of the B subunits is to facilitate the binding and entry of the attached A subunit into GM-1 -expressing cells.
  • the holotoxins are potent adjuvants for a range of antigens and can modulate different immune functions including antigen presentation, cytokine production, and B-cell switching, their practical use is limited by the toxicity of the A subunit.
  • LTB and CTB can be explained by the increased uptake of B subunit across GM-1 -expressing epithelial cells lining mucosal tracts, thereby enhancing the amount of antigen passively delivered to the MALT inductive sites and the subsequent stimulation of antigen-specific B- and T- lymphocytes.
  • LTB can also modulate immune activities such as cytokine production, lymphocyte apoptosis, and expression of B-cell activation molecules. These properties may also add to their effectiveness as adjuvants. What is clear is that the highly immunogenic nature of LTB and CTB and their ability to modulate lymphocyte activity is dependent upon their ability to bind GM-1.
  • Antigens can be physically attached to B5 subunits by either genetic or chemical means. Genetic fusion of epitopes to LTB has been successful in some cases, but genetic coupling of heterologous epitopes can interfere with the structure, secretion, GM-1 -binding and immunogenicity of the LTB fusion proteins. Also, there are limitations to the size and type of antigen that can be attached to LTB by genetic fusion. An alternative and more flexible approach is chemical coupling, which may be used to attach larger and a wider range of antigens, including polysaccharides.
  • CTB has been chemically coupled to antigens such as whole Sendai virus and purified Agl/II from Streptococcus mutans and these conjugates have been shown to stimulate strong immune responses at mucosal sites (gut, respiratory tract, genital tract) and in the circulation.
  • antigens such as whole Sendai virus and purified Agl/II from Streptococcus mutans and these conjugates have been shown to stimulate strong immune responses at mucosal sites (gut, respiratory tract, genital tract) and in the circulation.
  • the invention provides novel sequence modifications to recombinant CTB or other AB 5 -type B5 subunit proteins through site directed mutations, deletions or additions.
  • the invention also contemplates a method for producing said proteins which can be cross-linked chemically, hydrophobically, or genetically, or otherwise associated with an immunogen adjuvant, microcapsule, drug or immune response modifier in a manner in which the CTB product or other AB5-type B5 retains ganglioside specificity.
  • the recombinant B subunit proteins are specifically altered so that chemical conjugation to an immunogen, drug or immune response modifier occurs in a residue specific manner and can be attached without eliminating the ganglioside affinity of the resultant conjugate.
  • the recombinant B subunit proteins can be expressed and isolated in large amounts. This allows for a conjugate that is more homogeneous in composition and is known to bind to the ganglioside with an acceptable affinity.
  • the vaccine(s) derived from this conjugate thereby target the mucosal tissues and promote both systemic and mucosal immune responses.
  • the preferred embodiment of this invention is particularly advantageous for the recruitment of immunity to the predominant site of infection for infectious diseases, most of which typically colonize mucosal tissue surfaces.
  • One embodiment of the invention is a novel plasmid construct of a B5 expression system in which a B5 protein is expressed at high levels.
  • a recombinant cholera toxin B (rCTB) subunit protein including at least one mutation, addition, or deletion of residues between positions 1 -103 of CTB is disclosed.
  • the alteration allows chemical conjugation of said recombinant protein without interference to the ganglioside binding of CTB.
  • the mutation diminishes the ability of rCTB to combine at that site with any compound, drug, immunogen, immunomodulatory molecule, adjuvant or other bioactive molecule.
  • the compound can bind more specifically at another site and deliver these compounds to the mucosal epithelium.
  • the mutation, deletion or addition is to positions 1-103 of wild type CTB.
  • At least one mutation includes K23U, K34U, K43U, K62U, K63U, K69U, K81 U, K84U, C86U or K91U; wherein "U” is any amino acid that fails to promote chemical modification at those sites or wherein "U” represents the deletion of the residue, and the deletion of the amino acid results in a rCTB protein with a reduced ability to be covalently modified at those sites.
  • the at least one mutation, deletion or addition facilitates rCTB to combine at the site of the mutation, deletion or addition with any compound, drug, immunogen, immunomodulatory molecule, adjuvant or other bioactive molecule and to deliver the complex to the mucosal epithelium.
  • the mutation, deletion or addition is to positions 1-103 of wild type CTB.
  • a further embodiment of the invention is a recombinant cholera toxin B (rCTB) subunit protein including at least one mutation or deletion that reduces the number of potential chemical modification sites in the recombinant protein as compared to a wild type CTB protein.
  • the mutation or deletion is at positions 1-103 of CTB.
  • at least one mutation or addition increases the number of potential chemical modification sites in the recombinant protein at the mutation sites as compared to a wild type CTB protein.
  • the mutations or additions are at positions 1 -103 of CTB.
  • a further embodiment of the invention is a method of making a recombinant cholera toxin B (rCTB) subunit gene encoding a rCTB protein with a reduced number of modification sites as compared to a wild type CTB protein.
  • the method includes providing a cholera toxin B (CTB) subunit gene encoding a CTB protein; selecting codons encoding amino acid residues favoring chemical modification of the CTB protein; and mutating or deleting the codons such that the resulting amino acid residues are unfavorable for chemical modification.
  • CTB cholera toxin B
  • a further embodiment of the invention is a method of making a recombinant cholera toxin B (rCTB) subunit gene encoding a rCTB protein with an increase in chemical modification sites as compared to a wild type CTB protein, comprising providing a cholera toxin B (CTB) subunit gene encoding a CTB protein; selecting codons encoding amino acid residues unfavorable to chemical modification of the CTB protein; and mutating or adding said codons such that the resulting rCTB protein possesses favorable chemical modification capabilities; selecting codons encoding amino acid residues favorable to chemical modification of the CTB protein; and mutating or deleting said codons such that the resulting amino acids are incapable of chemical modification.
  • CTB cholera toxin B
  • a further embodiment of the invention is a method of producing a recombinant cholera toxin B (rCTB) subunit gene encoding a rCTB protein with decreased chemical modification sites as compared to a wild type CTB protein, comprising providing a cholera toxin B (CTB) subunit gene encoding a CTB protein; selecting codons encoding amino acid residues unfavorable to chemical modification of the CTB protein; mutating or adding said codons such that the resulting rCTB protein possesses favorable chemical modification capabilities; selecting codons encoding amino acid residues favorable to chemical modification of the CTB protein; and mutating or deleting said codons such that the resulting amino acids are incapable of chemical modification.
  • CTB cholera toxin B
  • a further embodiment of the invention is a method for producing a recombinant cholera toxin B (rCTB) subunit protein including the steps of obtaining a gene encoding an rCTB protein or mutated protein of the invention, adding a promoter, thereby producing an expression cassette; introducing the expression cassette into a suitable host cell, and cultivating the host cell under conditions whereby the expression cassette is translated into protein.
  • rCTB cholera toxin B
  • a further embodiment of the invention is a gene construct for producing a recombinant binding subunit protein of cholera toxin (CTB), having a promoter and a DNA sequence which encodes a rCTB protein operably linked in the proper reading frame.
  • CTB cholera toxin
  • a further embodiment of the invention is a method for producing a recombinant binding sub-unit protein of cholera toxin (CTB).
  • the method includes expressing a gene construct in a suitable host cell and recovering CTB or mutations thereof.
  • a further embodiment of the invention is the creation of complexes of rCTB or variants thereof and compounds of whole or part, live, killed or reconstituted bacterium or virus, virus-like particle, protein, peptide, glycoprotein, carbohydrate, polysaccharide, phospholipid, DNA, drug, biological response modifier, microparticles or adjuvant by genetic, covalent, hydrophobic or associative mechanisms.
  • a further embodiment of the invention is a gene fusion vector which includes a promoter, a DNA sequence encoding the cholera toxin binding subunit protein or mutant rCTB of the invention and an immunogenic peptide coding sequence, wherein the cholera toxin binding protein subunit and the immunogenic peptide coding sequences are operably linked in the proper reading frame, whereby a gene fusion protein results, and the gene fusion protein is expressed and secreted within inclusion bodies or medium.
  • a further embodiment of the invention is a method of generating an antibody or cellular immune response to an immunogen or immunogenic complex.
  • the method includes providing the recombinant CTB protein of the invention, modifying the protein covalently with a heterobifunctional cross-linking reagent with a first and a second functional groups, wherein the first functional group is in chemical association with the recombinant CTB protein, covalently modifying the second functional group covalently with the immunogen, and administering the CTB protein modified in such a way that the animal generates an immune response.
  • a further embodiment of the invention is a method of generating an antibody or cellular immune response to an immunogen or immunogenic complex including providing the recombinant CTB protein of the invention, modifying the protein with a dimeric cross-linking reagent with a first and a second functional groups, wherein the first functional group is in chemical association with the recombinant CTB protein, covalently modifying the second functional group with an epitope, and administering the protein to the host until an immune response is generated.
  • a further embodiment of the invention is a method of generating an antibody or cellular immune response to an immunogen or immunogenic complex which includes providing the recombinant CTB protein of the invention, modifying the protein hydrophobically by prenylation or by covalent linkage in a CTB site directed manner to an amphipathic side group, mixing with an immunogenic complex containing any Iipid or phospholipid micellar formulation, and administering the CTB-immunogen to the host until an immune response is generated.
  • a further embodiment of the invention is an rCTB expression vector including an MS-0 vector, and SEQ ID NO: 1.
  • the vector may be pML-CTBtacl .
  • a further embodiment of the invention is a method for generating an immune response to an immunogen comprising providing a recombinant AB5 toxin B protein, prenylating the toxin B protein, mixing the prenylated toxin B protein with an immunogen to produce a hydrophobically coupled protein, and administering the protein to an animal to generate an antibody or cellular response.
  • the AB5 toxin B protein may be cholera toxin B protein (CTB), E.
  • the AB5 toxin B protein is cholera toxin B protein (CTB).
  • a further embodiment of the invention is a method of making a recombinant AB5 toxin B (rB) subunit gene encoding a rB protein with an enhanced number of modifications sites as compared to the wild type rB protein, comprising providing a B subunit gene encoding a B protein, selecting codons encoding amino acid residues not involved in covalent modification of the B protein, and mutating said codons such that the resulting rB protein possesses enhanced modification capabilities.
  • rB recombinant AB5 toxin B
  • rB subunit gene encoding a rB protein with altered chemical modification capabilities as compared to the wild type B protein, including providing a toxin B (B) subunit gene encoding a B protein, selecting codons encoding amino acid residues which favor covalent modification of the B protein, mutating the codons such that the resulting rB protein possesses enhanced chemical modification capabilities at that site, selecting codons encoding amino acid residues which favor chemical modification of the B protein; and mutating the codons such that the resulting amino acids do not favor chemical modification at that site.
  • the rB protein is cholera toxin B protein (CTB), E. coli heat labile toxin B protein (LTB).
  • the mutations include changing lysine, histidine, arginine or cysteine residues to any other amino acid residues. In a further embodiment, the mutations include changing any amino acid to lysine, histidine, arginine or cysteine.
  • a further embodiment of the invention is a gene fusion vector comprising a promoter, a DNA sequence encoding an AB5 toxin ganglioside binding subunit protein and an immunogenic peptide coding sequence, wherein said AB5 toxin ganglioside binding protein subunit and said immunogenic peptide coding sequences are operably linked in the proper reading frame, whereby a gene fusion protein results; and said gene fusion protein is expressed and secreted within inclusion bodies or medium.
  • Figure 1 is the translated coding sequence of the rCTB protein produced by the MS-0 (Maxim Secretory -0) genetic expression vector (SEQ ID NOs: l and 2). The encoded protein is identical to the wild-type sequence from V. cholera strain 569B.
  • Figure 2 is a plasmid map illustrating the MS-0 plasmid.
  • Figure 3 is the amino acid sequence of rCTB (SEQ ID NO:2). further illustrating the predicted secondary structure, position of lysine residues, and regions involved in binding to GM-1.
  • the invention contemplates introducing mutations, such as amino acid additions or deletions, throughout the nucleic acid sequence of the B subunits from the family of AB5 toxins (hereinafter AB5 B subunit proteins) to produce mutant proteins that possess enhanced conjugation characteristics.
  • AB5 B subunit proteins AB5 B subunit proteins
  • the term "enhanced conjugation characteristics ' ' refers to an AB5 B subunit protein that can be conjugated by chemical or other means to drugs, immunogens, cytokines or other bioactive compounds such that the conjugated compound possesses increased bioactivity.
  • enhanced conjugation characteristics in an AB5 B subunit protein results from the mutations taught here that are designed to decrease steric hinderance or the formation of inappropriate quaternary structures as a consequence of the process of conjugation. In this way, these mutations maximize the availability of the ligand binding sites on the mutant AB5 B subunit proteins an conjugates composed thereof.
  • One benefit of using such mutant AB5 B subunit proteins is to improve the yield of bioactive structures following conjugation.
  • the invention describes mutants of AB5 B subunit proteins comprising single or multiple amino acid substitutions, deletions, or insertions, throughout its sequence that result in novel, predictable spatial orientations of the molecules to be conjugated relative to one another.
  • the invention further contemplates mutant AB5 B subunit proteins with enhanced or altered conjugation characteristics that enhance the bioactivity of the resulting conjugate.
  • Such a mutant AB5 B subunit protein coupled to an immunogen or other bioactive compound serves to enhance the compound's activity in a subject to whom the mutant protein conjugate is administered.
  • AB5 toxins consist of hexameric assemblies comprising a single catalytically active A- subunit and a pentamer of B-subunits.
  • the B-pentamer of these toxins is capable of target cell recognition and binding even in the absence of the A-subunit.
  • the toxin pentamers bind to saccharides, either to the olgosaccaride moieties of gangliosides in the cell membrane or to glycosylated proteins at the cell surface.
  • the class of AB5 toxins may be subdivided into families on the basis of sequence homology and catalytic activity.
  • One family, the cholera toxin (CT) family includes, in addition to CT itself, the E.
  • shiga toxin family comprises a number of toxins from Shigella dysenteriae and the shiga-like toxins (also known as verotoxins) from E.coli.
  • Other AB5 toxins include pertussis toxin from B. pertussis and the eukaryotic toxin ricin.
  • the AB5 toxin LTB illustrates one relationship between this family of proteins. LTB shares extensive homology with CTB. The two toxins share 80% amino acid sequence identity, similar receptor specificity, catalytic activity, and immunological properties.
  • AB5 proteins with little sequence identity such as the shiga and pertussis toxins still share a high degree of structural similarity. This was determined based on the structure of the toxins in complex with the pentasaccharide from the toxin receptor and based on crystallographically determined details of toxin-receptor binding interactions (see Merritt et al. Current Opinion in Structural Biology, 1995, 5: 165-171 ). Therefore, although other B5 subunit proteins can be distinct in amino acid sequence, they still possess comparable functional specificity. Some B5 holotoxins of this type are LT type lla and lib. Additionally.
  • the concepts taught in this application for rCTB may be applied to all examples of B5 subunits, some of which are shown below in Table 1.
  • the first CTB sequence shown (SEQ ID NO: 33) is the original sequence published by Sanchez and Holmgren that is identical to the one used in this application, except for the amino terminus. (SEQ ID NO:2).
  • the first LTB sequence (SEQ ID NO: 15) is derived from the sequence of the cloned gene.
  • the other sequences listed in the table are variants of either CTB or LTB found in the NCBI gene bank. The list is not intended to show all variants, but to demonstrate the natural variation among these toxins.
  • the invention also relates to nucleic acids molecules comprising polynucleotide sequences encoding mutant AB5 B subunit proteins, fragments or derivatives thereof.
  • the AB5 B subunit proteins, fragments or derivatives contemplated for use with the invention possess mucosal tissue binding or association capabilities. These sequences generally contain at least one base insertion, deletion or substitution, or combinations thereof that result in single or multiple amino acid addition, deletion and substitution relative to the wild type AB5 B subunit protein. Due to the degeneracy of nucleotide coding sequences, any other DNA sequences that encode the same amino acid sequence for a mutant subunit may be used in the practice of the invention.
  • AB5 B Subunit Gene Cloning
  • Polynucleotides encoding AB5 B subunits can be obtained by standard procedures from sources of cloned DNA, as would be represented by a "library" of biological clones, by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA purified from a desired cell type. Methods useful for conducting these procedures have been detailed by Sambrook et al., in Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989); by Glover, D.M. (ed.), in DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. (1985); and by Current Protocols in Molecular Biology. Eds.
  • PCR polymerase chain reaction
  • Synthetic oligonucleotides can be utilized as primers in a PCR protocol using RNA or DNA, or a cDNA library, as a source of target sequences.
  • the nucleic acid sequence being amplified can include cDNA or genomic DNA from any AB5 B toxin producing bacterium.
  • a segment of an AB5 B subunit After successful isolation or amplification of a polynucleotide encoding a segment of an AB5 B subunit, that segment can be molecularly cloned and sequenced, and utilized as a probe to isolate a complete cDNA or genomic clone. This, in turn, will permit characterization of the nucleotide sequence of the AB5 B subun it-encoding polynucleotide, and the production of the AB5 B subunit protein product for functional analysis and/or therapeutic or diagnostic use.
  • the identified and isolated polynucleotide can be inserted into an appropriate cloning vector for amplification of the gene sequence.
  • vector-host systems known in the art may be used for this purpose.
  • Possible vectors include plasmids or modified viruses. Of course, the vector system must be compatible with the host cell used in these procedures.
  • Such vectors include bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives or the pBLUESCRIPT vector (Stratagene, La Jolla, CA).
  • the insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment of interest into a cloning vector which has complementary cohesive termini.
  • the ends of the DNA molecules may be enzymatically modified.
  • any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences.
  • the cleaved vector and mutant subunit gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection or electroporation so that the copies of the vector containing the gene sequence of interest is increased.
  • the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.
  • transformation of host cells with recombinant DNA molecules that comprise the mutant subunit gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene.
  • the AB5 B subunit-encoding polynucleotide may be obtained in large quantities by growing transformed host organisms, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA. Copies of the gene are used in mutagenesis experiments to study the structure and function of mutant AB5 B subunit proteins. Mutagenesis
  • mutant AB5 B subunits, fragments and derivatives of the invention can be produced by various methods known in the art.
  • the manipulations which result in their production can occur at the gene or protein level.
  • the cloned coding region of the subunits can be modified by any of numerous strategies known in the art (see Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).
  • the polynucleotide sequence can be cleaved at appropriate sites using restriction endonucleases, followed by further enzymatic modification if desired, isolated, and ligated in vitro.
  • polynucleotide sequence encoding the subunits can be mutated in vitro or in vivo, to create variations in coding regions (e.g. amino acid substitutions), and/or to create and/or destroy translation, initiation, and/or termination sequences, and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification.
  • Any technique for mutagenesis known in the art can be used, including but not limited to, chemical mutagenesis, in vitro site-directed mutagenesis (Hutchinson, C. et al., 1978, J. Biol.
  • mutant subunit sequence may also be made at the protein level. Included within the scope of the invention are mutant AB5 B subunits that are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand.
  • mutant AB5 B peptide sequences or chemical analogs can be synthesized.
  • a peptide corresponding to a portion of a mutant subunit which comprises the desired mutated domain can be synthesized using an automated peptide synthesizer.
  • nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the mutant subunit sequence.
  • Non-classical amino acids include but are not limited to the D-isomers of the common amino acids, ⁇ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, ⁇ -Abu, ⁇ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t- butylalanine, phenylglycine, cyclohexylalanine, ⁇ -alanine, fluoro-amino acids, designer amino acids such as ⁇ -methyl amino acids, C ⁇ -methyl amino acids, N ⁇ -methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary). Expression of Mut
  • polynucleotide sequence encoding a mutant subunit of CTB or a functionally active fragment or other derivative thereof can be inserted into an appropriate expression vector.
  • appropriate expression vectors will contain the necessary elements for the transcription and translation of the inserted protein-coding sequence.
  • the necessary transcriptional and translational signals may also be supplied by the native AB5 B subunit cDNA or gene, and/or genomic sequences flanking the subunit gene.
  • a variety of host-vector systems may be utilized to express the protein-coding sequence.
  • yeast containing vectors capable of replication in yeast include established or experimental bacterial expression systems; mammalian cell systems infected with a recombinant virus such as a vaccinia virus or adenovirus, insect cell systems infected with a virus such as a recombinant baculovirus, and microorganisms such as yeast containing vectors capable of replication in yeast.
  • a recombinant virus such as a vaccinia virus or adenovirus
  • insect cell systems infected with a virus such as a recombinant baculovirus
  • microorganisms such as yeast containing vectors capable of replication in yeast.
  • the expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used. In specific embodiments, a mutant subunit coding region or a sequence encoding a mutated and functionally active portion of the respective mutant subunit is expressed.
  • any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA synthetic techniques. Expression of polynucleotide sequences encoding mutant AB5 B subunits or peptide fragments thereof may be regulated by a second polynucleotide sequence so that the mutant subunit(s) or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a mutant AB5 B subunit or peptide fragments thereof may be controlled by any promoter/enhancer element known in the art.
  • Promoters which may be used include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981 , Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto. et al.. 1980. Cell 22:787-797). the herpes thymidine kinase promoter (Wagner et al., 1981 , Proc. Natl. Acad. Sci. U.S.A. 78: 1441 -1445), and the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42).
  • a vector is used that comprises a promoter operably linked to the coding region of a mutant AB5 B subunit, and one or more selectable markers (e.g., an antibiotic resistance gene).
  • a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers. In this matter, expression of the genetically engineered mutant subunits may be controlled.
  • different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins). Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein.
  • different vector/host expression systems may effect processing reactions to different extents.
  • the gene product(s) can be purified and analyzed.
  • the analysis is achieved by assays based on the physical or functional properties of the product, including radioactive labelling of the product followed by analysis by gel electrophoresis, immunoassay or other techniques useful for detecting the biological activity of the mutant subunit.
  • mutant AB5 B subunits, fragments or other derivatives thereof, alone or conjugated to an immunogenic molecule or some other protein of interest may be used as an immunogen to generate antibodies which immunospecifically bind such an immunogen.
  • Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.
  • antibodies to a mutant AB5 B subunit, such as CTB are produced.
  • antibodies to a domain of a mutant subunit are produced.
  • antibodies to the immunogen are produced.
  • Various procedures known in the art may be used for the production of polyclonal antibodies directed against mutant AB5 B subunits, fragments, or other derivatives thereof.
  • various host animals can be immunized by injection with the mutant subunits produced with the methods described herein.
  • Appropriate host animals include rabbits, mice, rats, other mammals, as well as birds such as chickens.
  • adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's adjuvant (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic poiyols, polyanions, caprylic acid glycerides, peptides, polyoxyethylene sorbitan monoesters, oil and water emulsions, liposomes, poly-L-lactide co- glycolide (PLG) microspheres, protein carriers such as keyhole limpet hemocyanin or diphtheria toxin mutants, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette- Guerin) and corynebacterium parvum.
  • BCG Bacille Calmette- Guerin
  • any technique which provides for the production of antibody molecules by continuous cell lines in culture can be used.
  • the trioma technique the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
  • monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545).
  • Human antibodies can be used and can be obtained by using human hybridomas (Cote et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985. in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96).
  • techniques developed for the production of "chimeric antibodies” (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A.
  • Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
  • such fragments include but are not limited to: the F(ab')2 fragment which can be produced by pepsin digestion of the antibody molecule, the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments.
  • screening for the desired antibody can be accomplished using standard techniques known in the art.
  • the ELISA enzyme-linked immunosorbent assay
  • selection of an antibody that specifically binds a mutant AB5 B subunit, but which does not specifically bind the wild type protein one can select on the basis of positive binding to the mutant and a lack of binding to the wild type protein.
  • Antibodies specific for a domain of a mutant AB5 B subunit, or fragment thereof are also provided by the invention.
  • the foregoing antibodies can be used in methods known in the art relating to the localization and activity of the mutant AB5 B subunits of the invention. These methods can involve labeling of the proteins, measuring levels thereof in appropriate physiological samples in diagnostic methods.
  • Described herein are methods for analyzing the structure and function of mutant AB5 B subunits and for analyzing the in vitro activities and in vivo biological functions of the foregoing.
  • mutant AB5 B subunit Once a mutant AB5 B subunit is identified, it can be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique useful for purifying proteins.
  • chromatography e.g., ion exchange, affinity, and sizing column chromatography
  • centrifugation e.g., centrifugation, differential solubility, or by any other standard technique useful for purifying proteins.
  • the ammo acid sequence of the subun ⁇ t(s) can be determined using standard techniques for protein sequencing, including the use of an automated amino acid sequencer
  • a mutant AB5 B subunit, derivatives and fragments thereof can be assayed by various methods known in the art
  • various immunoassays known in the art can be used These immunoassays include competitive and non- competitive assay systems using techniques such as radio-immunoassays, ELISA, "sandwich” immunoassays, lmmunoradiomet ⁇ c assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or ladioisotope labels, for example), Western blots, precipitation reactions, agglutination assays (e g , gel agglutination assays, hemagglutination assays
  • the mutant AB5 B subunit may be coupled to an immunogen of choice
  • the mutant AB5 B subunit proteins described herein are combined in a desired weight ratio so as to produce a vaccine that can elicit an optimal protective mucosal and systemic immune response from an immunized subject
  • the mutant AB5 B subunit and the immunogen component are mixed in a ratio in which the proportion of carrier component exceeds that of the immunogen, for example, at a molecular weight ratio of about 500,000:1.
  • the mutant AB5 B subunit and the immunogenic component are mixed in a molecular weight ratio of about 100,000: 1.
  • the mutant AB5 B subunit and the immunogen are mixed in a molecular weight ratio of about 1000: 1, or 100: 1, or 10: 1.
  • the molecular weight ratio can be that of 1 : 1.
  • the components of the vaccine can also be combined in a ratio where the proportion of carrier component is less than that of the immunogen.
  • small compounds or peptides conjugated to a mutant rCtB described herein can be conjugated at a ratio of 1 rCtB homopentamer to 5. 10 or more immunogenic molecules.
  • Cross-linking reagents for use with mutant AB5 B subunits There are a variety of cross-linking procedures and reagents available to conjugate bioactive compounds, such as immunogens and vaccines to mutant AB5 B subunits.
  • Cross-linking procedures generally employ bifunctional reagents that modify amino acid side-chains. Typical amino acids modified include cysteine, lysine, and histamine. although any modifiable amino acid is contemplated for use with the invention.
  • Bifunctional reagents are often classified on the basis of (i) chemical specificity; (ii) length of cross-bridge formed; (iii) whether the compound is a homo-bifunctional or hetero-bifunctional compound; (iv) whether the groups are chemically or photochemically reactive; and (v) whether the reagents contain a cleavable bond.
  • cross-linking reagents are reactive with amino- groups or sulphydryl- containing side chains of amino acids, for example, as with lysine or cysteine side chains.
  • the choice of a cross- linking reagent will depend on the target amino acid in both the ligand to be cross-linked and the target AB5 B subunit.
  • Cross-linking reagents for use with the invention modify target amino acid residues, produce a cross-link between the immunogen of choice and a mutant AB5 B subunit that produces an immunogenic product, and does not substantially reduce the ligand binding affinity of the mutant AB5 B subunit.
  • An example of a cross-linking technique for lysine and cysteine residues is shown in Example 5.
  • Suitable cross- linking reagents include cleavable and non-cleavable cross-linking reagents.
  • Some suitable cleavable cross-linking reagents that primarily react with primary amines such as lysine side chains include: dimethyl-3,3'-dithiobispropionimidate (DTBP), 2-iminothiolane (2-IT), /V-succinimidyl- (4-azidophenyl)-l,3-dithiopropionate (SADP), ethyl-4-azidophenyl-l,4-dithiobutyrimidiate (EADB), l-[ «-2-hydroxy-5-azidobenzoyl)-2-aminoethyl]-4-(N-hydroxysuccinimidyl)-succinate (HAHS), and 7V-[-4-/j-azidophenylazo)benzo
  • DTBP dimethyl-3,3'-d
  • a suitable non-cleavable cross-linking agent that is specific for primary amines is succinimidyl trans- 4-(maleimidylmethyI) cyclohexane-1-carbodylate (SMCC).
  • suitable cleavable cross- linking reagents that are specific for cysteine side chains include: N-(4-azidophenyl)phthalimide (APTP), N-[4-(p-azidosalicylamido)butyl]-3'-(2'-pyridyldithio)propionamide (APDP), NN'-bis(4- azidobenzoyl)cystine (ABC)2, and N-(4-azidobenzoylglycI)-S-(2-thiopyridyl)cysteine (AGTC).
  • APTP N-(4-azidophenyl)phthalimide
  • APDP N-[4-(p-azidosalicylamid
  • Cross-linking with mutant AB5 B subunit proteins can be induced with an aldehyde.
  • suitable aldehydes include glutaraldehyde, formaldehyde, glyceraldehyde, acetaldehyde, phenylaldehyde, valeraldehyde, or 3,4-dihydroxyphenylacetaldehyde.
  • ketones can be used to modify and cross-link the vaccine components. Suitable ketones would include acetone, methyl ethyl ketone, 3-pentanone, or any other ketone known to one of ordinary skill in the art.
  • cross-linking or conjugation agents including N-succinimidyl 3-[2-pyridyldithio] propionate (SPDP), ultraviolet cross-linking and other protein cross-linking methods known in the art.
  • SPDP N-succinimidyl 3-[2-pyridyldithio] propionate
  • Mutations to the ganglioside binding sites of the B subunits of the AB5 toxins might adversely affect the ganglioside affinity characteristics of the protein.
  • CTB subunit residues influence receptor binding.
  • the mutation G33D ablates ganglioside affinity yet appears to retain polyglycosylceramide affinity (Backstrom et al. 1997 Mol Microbiol 24:489-497).
  • G33R mutations retain ganglioside affinity (Merritt et al. 1995 Structure 3:561-570).
  • Alternative substitutions may have surprising effects on the quaternary structure of CTB. For example, G35D substitutions diminish homopentamer formation (Merritt et al. 1995.
  • CTB subunit residues influence receptor binding.
  • the mutation G33D ablates ganglioside affinity yet appears to retain polyglycosylceramide affinity (Backstrom et al. 1997. Mol Microbiol 24:489-497).
  • G33R mutations retain ganglioside affinity (Merritt et al. 1995. Structure 3:561-570).
  • Alternative substitutions may have surprising effects on the quaternary structure of CTB. For example, G35D substitutions diminish homopentamer formation (Merritt et al. 1995.
  • Amino acids 2-7 form a loop on the outer surface of rCTB.
  • Residues Gin 3, Asn 4, Thr 6, and Asn7 all possess polar side chains which face out from the molecule. These side chains can be replaced with another amino acid to introduce a chemically modifiable amino acid side chains into this region.
  • Residues 10-14 are reported to form an amino acid sequence with ganglioside receptor affinity. Mutations to this site, particularly HI 3, might create a more hydrophobic rCTB (Merritt et al. 1995. Structure 3:561-570).
  • Amino acids 14-20 are thought to form a /3-sheet on the outer surface of rCTB with many of the side chains facing outward.
  • Residues 21 -25 of CTB form a surface loop on the surface of rCTB.
  • the loop is comprised of Asn 21 , an uncharged polar amine, Asp 22, an acidic side chain, and Lys 23. a basic amine.
  • Each side group is thought to face outward from the surface of the protein. The orientation of this residue suggests that it may play some role in structural stability of the monomer.
  • Amino acid residue Phe 25 also faces outward from the molecular surface with its uncharged, nonpolar benzyl ring and might be mutated to introduce a modifiable amino acid into the sequence of the protein.
  • Residues 25-30 form a / -pleated sheet within the CTB monomer that is not accessible to the molecular surface. Mutations to this site might be expected to disrupt the quaternary structure of rCTB. Residues 31-35 are referenced within the specification with regard to the Gm- 1 receptor. Residues 36-40 of CTB are thought to form an internal ⁇ -pleated sheet as in 25-30. Residues 41 -44 form a surface exposed loop containing Lys 43 next to Asn 44. Asn 44 may be a good candidate for lysine due to its location, charge, and side chain similarity to Lys 43.
  • Residues 45-55 are thought to form a ⁇ -pleated sheet within the monomer.
  • Residues 55-64 are thought to form an insert permissive site. Lysmes at positions 62 and 63 within this region may be deleted or mutated without apparent adverse effect on the ganglioside binding affinity of rCTB mutants (Backstrom et al. 1995, Gene 165: 163-171 ).
  • Residues 60-78 form an internal hydrophobic ⁇ -helix in the homopentamer. Significant changes to this sequence, particularly to residues 65-78, might be expected to interfere with homopentamer formation.
  • Residues 79-85 of CTB form a loop on the surface of the CTB monomer.
  • Lys 81 and Lys 84 face outward from the monomeric structure. Lys 81 and 84 would appear to be an optimal target residues for conjugation due to their position contralateral to the receptor and surface location within the monomer.
  • CTB residues 86-95 form internalized side chains and inferior loop contact points with Gm- 1, encompass the Lys 91 successfully produced and claimed herein.
  • CTB residues 96-103 form an internal sheet which ends with an optimally positioned Asn 103.
  • This Asn 103 is a key target for Lys insertion due to its similar charge, structure and on the molecule.
  • a large number of mutations can result in a mutant CTB protein with altered conjugation characteristics. Some mutants will preserve, enhance, or at least not detrimentally reduce the Gm-1 binding affinity of the mutant CTB proteins described herein. On the other hand, some loss of Gm-1 affinity is tolerable given the extraordinarily high initial affinity (4.6 x)
  • Binding affinity of the mutant proteins can be determined using a number of assays well known in the art.
  • Mutants of Recombinant cholera Toxin Subunit B The invention contemplates mutations, substitutions, deletions, or insertions of one, two, three, four or more amino acid residues in the amino acid sequence of cholera toxin subunit B.
  • the full length amino acid sequence of wild type rCTB is shown in FIGURE 1 (SEQ ID NO: 2).
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule.
  • Such mutations include: T1X, P2X, Q3X, N4X, I5X, T6X, D7X, L8X, C9X, A10X, El IX, Y12X, H13X, N 14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, G33X, K34X, R35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, N44X, G45X, A46X, T47X, F48X, Q49X, V50X, E51X, V52X, P53X, G54X, S55X, Q56X, H57X, I58X, D59X, S60X, Q61X, K62X
  • A102X, N 103X wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid.
  • the "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
  • Lvsine Substitutions in rCTB Conjugation of rCTB to immunogens derived from infectious diseases can create vaccines which induce protection following mucosal delivery.
  • Classic conjugation chemistry targets are reactive amino acid side chain groups such as primary amines, carboxylic acids, aldehydes, or sulfhydryls.
  • the primary reactive amino acids in rCTB are lysines (see Figure 3).
  • the B subunit of cholera toxin contains nine (9) lysine amino acid residues. A number of these residues are contemplated to play a role in facilitating conjugation of bioactive compounds to the rCTB protein. These lysine residues are distributed at various places throughout the CTB sequence.
  • lysine residues that are near the Gm-1 binding site can couple to a bioactive compound of interest in a conformation which interferes with ganglioside binding.
  • any lysine residues to which the bioactive compound is coupled may induce a conformational change upon conjugation, which prevents or disrupts the formation of the quaternary structure required for ganglioside binding. Accordingly, a number of mutant rCTB proteins with increased or decreased numbers of conjugation sites as compared to the wild type form of the protein are disclosed herein.
  • the present approach involves directing the covalent linkage of an AB5 B subunit carrier and a bioactive molecule such that the bioactive molecule does not interfere with the ganglioside site of CTB.
  • Site directed mutagenesis was employed to create a panel of mutations at Lys91 of the rCTB coding sequence. These mutations resulted in several mutants which produce levels of protein, in vitro, comparable to those of the wild type and which can effectively deliver bioactive CTB-immunogen complexes to the mucosal immune system.
  • one embodiment discussed herein articulates a number of mutant rCTB proteins with amino acid substitutions that replace the lysine residues found in the wild type rCtB protein.
  • the invention contemplates recombinant CTB proteins with one or more of the following amino acid substitutions: K23X, K34X, K43X, K62X, K63X, K69X, K81X, K84X, and K91X; wherein "X" is any amino acid that results in a rCTB protein with a reduced ability to conjugate at the mutant sites.
  • These mutants are also contemplated to maintain a substantial degree of Gm-1 binding affinity as compared to the wild type or unmutated form of the protein.
  • some loss of affinity is allowable due to the extraordinarily high initial affinity (4.6 x 10" 1 ) of the wild type CTB for the Gm-1 receptor.
  • residues There are a number of lysine residues that are thought to result in particularly deleterious conjugation events given the proximity of these residues to the Gm-1 binding site. These residues include K34, K62, K63, and K91. Mutation of these residues favors conjugation events that will not interfere with Gm-1 binding affinity.
  • the invention further contemplates mutating the lysine residue at K69 to eliminate conjugation at this position.
  • Lysine 69 is thought to be distal from the Gm-1 binding site; however, conjugation to this residue might reduce rCtB homopentamer self-assembly. Incomplete quaternary structure formation is known to diminish Gm-1 affinity and likely also diminishes the bioactivity of a rCTB conjugated molecule.
  • the remaining lysine residues in CTB are K23, K43, K81, and K84. Each of these residues are contemplated as acceptable sites for conjugation. One or more of these residues can be mutated to reduce the total number of sites for conjugation.
  • Lys91 was the most reactive of all lysine residues in CTB when reacted with "small" (fluorescent) molecular probes.
  • Lys91 is positioned proximal to the terminal galactose residue of Gm-1. Therefore, conjugation of large molecular weight bioactive molecules is likely to result in steric hinderance of the Gm-1 binding site of rCTB.
  • reaction of larger molecular weight compounds with Lys69 which is located within the hydrophobic core of the pentamer, would disfavor reformation of bioactive CTB homopentamers.
  • Lys91 possesses a basic amino side chain with which the hydroxylated galactose of Gm-1 may interact and facilitate the affinity of rCTB for Gm-1.
  • a knockout of Lys91 might therefore be expected to significantly decrease the affinity of the mutant rCTB for Gm-1 and effect a decrease in recombinant production levels. Lvsine additions in rCTB
  • the invention further contemplates the addition of amino acid residues throughout the amino acid sequence of rCTB to direct conjugation of immunogens, immunomodulators, drugs, or other bioactive molecules, to specified sites within rCTB.
  • Any residue of rCTB can be mutated to introduce an amino acid residue that promotes acceptable conjugation events. Examples of these mutations include Q3X, N4X, T6X. N7X, H18X, N21X, F25X, N44X, M101X, and N103X wherein "X" is any amino acid that results in the addition of an acceptable conjugation site.
  • suitable amino acids for use at these sites include lysine and cysteine.
  • a further approach to specific chemical coupling or site-directed chemical coupling is to create a site for chemical coupling using a cysteine residue rather than a lysine residue. Accordingly, the following cysteine insertions are created: H18C and MI OI C.
  • the site-directed mutagenesis is performed as in Examples 1 -2.
  • Example 5 provides techniques for chemically coupling these residues to an immunogen of interest. Mutants in the N-terminus of rCTB
  • the wild type amino acid sequence of rCTB is shown in Figure 1.
  • the invention contemplates various mutations throughout the rCTB amino acid sequence.
  • one or more mutations are introduced into the N-terminus of the protein sequence.
  • an alanine residue is introduced at the first position of the rCTB amino acid sequence.
  • Introduction of this particular amino acid creates a defined signal sequence cleavage site, as opposed to the threonine residue at the amino terminus of the wild type form of rCTB. This cleavage site can be important in post-translational modifications. Mutants of other CTB family members identified by NCBI accession number
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GL758351 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule.
  • Such mutants include: MIX, I2X, K3X, L4X, K5X, F6X, G7X, V8X, F9X, F10X, Tl IX, V12X, L13X, L14X, S15X, S16X, A17X, Y18X, A19X, H20X, G21X, T22X, P23X, Q24X, N25X, I26X, T27X, D28X, L29X, C30X, A31X, E32X, S33X, H34X, N35X, T36X, Q37X, I38X, Y39X, T40X, L41X, N42X, D43X. K44X, I45X, F46X.
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI:758351 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
  • the amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI: 1827850 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule.
  • Such mutants include: T1X, P2X, Q3X.
  • the "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 1827850 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
  • the amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GL808900 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule.
  • Such mutations include: MIX, I2X, K3X, L4X, K5X, F6X, G7X, V8X, F9X, F10X, Tl IX, V12X, L13X, L14X, S15X, S16X, A17X, Y18X, A19X, H20X, G21X, T22X, P23X, Q24X, N25X, I26X, T27X, D28X, L29X, C30X, A3 IX, E32X, Y33X, H34X, N35X, T36X, Q37X, I38X, H39X.
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 808900 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm- 1 binding activity.
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GL229616 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule.
  • Such mutations include: T1 X, P2X, E3X, N4X, I5X, T6X, D7X, L8X, C9X, A10X, El IX, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, N22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, G33X, K34X, R35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, D44X, G45X, A46X, T47X, F48X, E49X, V50X, E51X, V52X, P53X, G54X, S55X, E56X, H57X, I58X, D59X, S60X, E61X, K62
  • the "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 229616 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
  • the amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GL998409 without deleterious effect to the ganglioside (Gm-1 ) binding affinity of the recombinantly produced molecule.
  • Such mutations include: T1X, P2X, Q3X, N4X, I5X, T6X, D7X, L8X, C9X, A10X, El IX, Y12X, H13X, N14X, T15X, Q16X, I17X, Y18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, G33X, K34X, R35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, N44X, G45X, A46X, I47X, F48X, Q49X, V50X, E51X, V52X.
  • the "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 998409 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GL2144685 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule.
  • Such mutations include: MIX, I2X, K3X, L4X, K5X, F6X, G7X, V8X, F9X, F10X, Tl IX, V12X, L13X, L14X, S15X, S16X, A17X, Y18X, A19X, H20X, G21X, T22X, P23X, Q24X, N25X, I26X, T27X, D28X.
  • the "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB G 2144685 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm- 1 binding activity.
  • the amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GL 142151 1 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule.
  • Such mutations include: T1 X, P2X, Q3X, N4X, I5X, T6X, D7X, L8X, C9X, A10X, El IX, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, D33X, K34X, R35X, E36X, M37X, A38X, I39X, I40X, T41X.
  • A98X, I99X, S100X, M101X, A102X, N103X wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid.
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 142151 1 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GL48890 (classic 569B) without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule.
  • Such mutations include: MI X, I2X, K3X, L4X, K5X, F6X, G7X. V8X, F9X, F10X, Tl I X, V12X, L13X, L14X, S15X, S16X, A17X, Y18X, A19X, H20X.
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 48890 (classic 569B) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
  • the amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB G 2781121 (Ogawa 41 ) without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule.
  • Such mutations include: MI X, T2X, P3X, Q4X, N5X, I6X, T7X, D8X, L9X, C10X, A1 1X, E12X, Y13X, H14X, N 15X, T16X, Q17X, I18X, H19X, T20X, L21X, N22X, D23X, K24X, I25X, F26X. S27X, Y28X, T29X, E30X, S3 I X, L32X, A33X.
  • the "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 2781 121 (Ogawa 41) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI: 1421525 (Ogawa 41 R35D) without deleterious effect to the ganglioside (Gm-1 ) binding affinity of the recombinantly produced molecule.
  • Such mutations include: T1 X, P2X, Q3X, N4X, I5X, T6X, D7X, L8X, C9X, A10X, El IX, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, G33X, K34X, D35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, N44X, G45X, A46X, T47X, F48X, Q49X, V50X, E51 X, V52X, P53X, G54X, S55X, Q56X, H57X, I58X, D59X, S60X, Q61X, K
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 1421525 (Ogawa 41 R35D) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm- 1 binding activity. Mutants of LTB and LTB family members identified by NCBI accession number
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GL3062900 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule.
  • Such mutations include: MIX, N2X, K3X, V4X, K5X, C6X, Y7X, V8X, L9X. F10X, TU X, A12X. L13X, L14X, S15X, S 16X, L17X, C 18X, A19X, Y20X, G21 X, A22X, P23X, Q24X, S25X, I26X, T27X, E28X.
  • the "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GL3062900 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI: 1 169505 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule.
  • Such mutations include: MIX, N2X, K3X, V4X, K5X, C6X, Y7X, V8X, L9X, F10X, TUX, A12X, L13X, L14X, S15X, S16X, L17X, Y18X, A19X, H20X, G21X, A22X, P23X, Q24X, T25X, I26X, T27X, E28X, L29X, C30X, S3 IX, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, S47X, Y48X, T49X, E50X, S51X, M52X, A53X, G54X, K55X, R56X, E57X, M58X, V59X, I60X, I61X,
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI: 1 169505 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
  • the amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI : 1395122 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule.
  • Such mutations include: MIX, N2X. K3X, V4X.
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI: 1395122 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
  • amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI: 145833 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule.
  • Such mutations include: MIX, N2X, K3X, V4X, K5X, C6X, Y7X, V8X, L9X, F10X, TUX, A12X, L13X, L14X, S15X, S16X, L17X, Y18X, A19X, H20X, G21X, A22X, P23X, Q24X, T25X, I26X, T27X, E28X, L29X, C30X, S3 IX, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, S47X, Y48X, T49X, E50X, S51X, M52X, A53X, G54X, K55X, R56X, E57X, M58X.
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI: 145833 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
  • amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI: 1648865 (LT87) without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule.
  • Such mutations include: MI X, N2X, K3X. V4X, K5X.
  • the "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI: 1648865 (LT87) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
  • the amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GL223254 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule.
  • Such mutations include: MIX, N2X, K3X, V4X, K5X, C6X, Y7X, V8X, L9X, F10X, TUX, A12X, L13X, L14X, S15X, S16X, L17X, Y18X, A19X, H20X, G21X, A22X, P23X, Q24X, T25X, I26X, T27X, E28X, L29X, C30X, S31X, E32X, Y33X, R34X, N35X. T36X, Q37X. I38X.
  • the "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GL223254 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
  • amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GL408996 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule.
  • Such mutations include: MIX, N2X, K3X, V4X, K5X, C6X, Y7X, V8X, L9X. F10X, TUX, A12X, L13X, L14X, S15X, S16X, L17X.
  • the "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GL408996 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GL494265 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule.
  • Such mutations include.
  • amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:69630 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule.
  • Such mutations include: MI X, N2X, K3X, V4X, K5X, C6X, Y7X, V8X, L9X, F10X, TUX, A12X, L13X, L14X, S15X, S16X, L17X, Y18X, A19X, H20X, G21 X, A22X, P23X, Q24X, T25X, I26X, T27X, Q28X, L29X, C30X, S3 IX, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, S47X, Y48X, T49X, E50X, S51X, M52X, A53X, G54X, K55X, R56X, E57X, M58X, V59X, I60X, 16 I
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GL69630 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity. Mutants of LT-IIa
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLT-IIa NCBI Accession No. GI: 146671 without deleterious effect to the ganglioside (GDlb, among others) binding affinity of the recombinantly produced molecule.
  • Such mutations include: MI X, S2X, S3X, K4X, K5X, I6X, I7X, G8X, A9X, F10X, V1 1X, L12X, M 13X, T14X, G15X, I 16X, L17X, S18X, G19X, Q20X, V21X, Y22X, A23X, G24X, V25X, S26X, E27X, H28X, F29X, R30X, N3 IX, I32X, C33X, N34X, Q35X, T36X, T37X, A38X, D39X, I40X, V41X, A42X, G43X, V44X, Q45X, L46X, K47X, K48X, Y49X, I50X, A51X, D52X, V53X, N54X, T55X, N56X, T57X, R58X.
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLT-IIa with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its GDI b binding activity. Mutants of LT-IIb
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLT-IIb NCBI accession no. GL576584 without deleterious effect to the ganglioside (GDIa among others) binding affinity of the recombinantly produced molecule.
  • Such mutations include: MIX, S2X, F3X, K4X, K5X, I6X, I7X, K8X, A9X, F10X, VI I X, I12X, M13X, A14X, A15X, L16X, V17X, S18X, V19X, Q20X, A21X, H22X, A23X, G24X, A25X, S26X, Q27X, F28X, F29X, K30X, D31X, N32X, C33X, N34X, R35X, T36X, T37X, A38X, S39X, L40X, V41X, E42X, G43X, V44X, E45X.
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLT-IIb with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside GDIa binding activity. Mutants of Shiga toxin Beta subunit
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of Shiga toxin Beta subunit NCBI Accession No. GI: 152784 without deleterious effect to the carbohydrate binding affinity of the recombinantly produced molecule for Gal alpha 1 — 4Gal beta 1 — 4Glc and globotrioside trisaccharides.
  • Such mutations include: MIX, K2X, K3X, T4X, L5X.
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant Shiga toxin Beta subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its carbohydrate binding activity. Mutants of verotoxin (Shiga-like toxin) beta subunit from E. coli
  • amino acid substitutions contemplated in the invention encompass any such substitution. deletion, or insertion that selectively alters the conjugation characteristics of Shiga-like toxin Beta subunit from E. coli NCBI Accession No. GF4877349 without deleterious effect to the carbohydrate binding affinity for globotriaosyl ceramide, Gb3 or blood group PI antigenic trisaccharide of the recombinantly produced molecule.
  • Such mutations include: MIX, K2X, K3X, I4X, F5X, V6X, A7X, A8X, L9X, F10X, A1 1X, F12X, V13X, S14X, V15X, N16X, A17X, M18X, A19X, A20X, D21X, C22X, A23X, K24X, G25X, K26X, I27X, E28X, F29X, S30X, K31X, Y32X, N33X, E34X, N35X, D36X, T37X, F38X, T39X, V40X, K41X, V42X, A43X, G44X, K45X, E46X, Y47X, W48X, T49X, N50X, R51 X, W52X, N53X, L54X, Q55X, P56X, L57X, L58X, Q59X.
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant Shiga-like toxin Beta subunit from E. coli with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its carbohydrate binding activity. Mutants of pertussis toxin B subunits
  • amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin S2 subunit NCBI Accession No. GI: 144070 without deleterious effect to the ganglioside (sialoglycoproteins) binding affinity of the recombinantly produced molecule.
  • Such mutations include: MI X, P2X, I3X, D4X, R5X, K6X, T7X, L8X, C9X, H10X, LUX, L12X, S13X, V14X, L15X, P16X, L17X, A18X, L19X, L20X, G21X, S22X, H23X, V24X, A25X, R26X, A27X, S28X, T29X, P30X, G31 X, I32X, V33X, I34X, P35X, P36X, Q37X, E38X, Q39X, I40X, T41X, Q42X, H43X, G44X, S45X, P46X, Y47X, G48X, R49X, C50X, A51X, N52X, K53X, T54X, R55X, A56X, L57X, T58X, V59X, A60X, E61 X, L62
  • P124X A125X, T126X. D127X, H128X, Y129X, Y130X, S131X, N132X, V133X, T134X, A135X, T136X, R137X, L138X, L139X. S140X, S141 X, T142X, N143X.
  • the “X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin S2 subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside (sialoglycoproteins) binding activity.
  • the amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin S3 subunit NCBI Accession No.
  • Such mutations include: MIX, L2X, I3X, N4X, N5X, K6X, K7X, L8X, L9X, H10X, HI IX, I12X, L13X, P14X, II 5X, L16X, V17X, L18X, A19X, L20X, L21X, G22X, M23X, R24X, T25X, A26X, Q27X, A28X, V29X, A30X, P31X, G32X, I33X, V34X, I35X, P36X, P37X, K38X, A39X, L40X, F41X, T42X, Q43X, Q44X, G45X, G46X, A47X, Y48X, G49X, R50X, C51X, P
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin S3 subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside (sialoglycoproteins) binding activity.
  • amino acid substitutions further encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin S4 subunit NCBI Accession No. GI: 144070 without deleterious effect to the ganglioside (sialoglycoproteins) binding affinity of the recombinantly produced molecule.
  • Such mutations include: M I X, L2X, R3X, R4X.
  • the "X” represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin S4 subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside (sialoglycoproteins) binding activity.
  • amino acid substitutions contemplated in the invention likewise encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin S5 subunit NCBI Accession No. GI: 144070 without deleterious effect to the ganglioside (sialoglycoproteins) binding affinity of the recombinantly produced molecule.
  • Such mutations include: MI X, Q2X, R3X, Q4X, A5X, G6X, L7X, P8X, L9X, K10X, Al I X, N 12X, P13X, M14X, H15X, T16X, I 17X, A18X.
  • the "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin S5 subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside (sialoglycoproteins) binding activity.
  • Lvsine Substitutions in the rCTB. rLTB, Shiga, Shiga-like, and pertussis family Conjugation of members of the rCTB, rLTB, Shiga, Shiga-like, and pertussis family to immunogens derived from infectious diseases can create vaccines which induce protection following mucosal delivery.
  • Classic conjugation chemistry targets are reactive amino acid side chain groups such as primary amines, carboxylic acids, aldehydes, or sulfhydryls.
  • the lysine residues are distributed at various places throughout the sequence. Those lysine residues that are near the Gm-1 binding site can couple to the ligand in a conformation which interferes with ganglioside binding. Accordingly, the invention articulates a number of mutant conjugation characteristics, primarily at lysine residues found in the rCTB protein family.
  • the present approach involves the idea of directing the covalent linkage of carrier and immunogen away from the ganglioside receptor of CTB family.
  • Site directed mutagenesis is employed to create a panel of mutations at various lysines of the rCTB family coding sequences. These mutations will result in mutants which produce variable levels of protein, in vitro, comparable to those of the wild type and which can effectively deliver bioactive CTB- immunogen complexes to the mucosal immune system.
  • the invention articulates a number of mutant rCTB family proteins that with amino acid substitutions that replace the lysine residues found in the wild type rCTB family protein.
  • the following amino acid substitutions are contemplated for rCTB family proteins G 758351 , 808900, 2144685, and 48890 (wherein "X” is any amino acid that results in a rCTB protein with a reduced ability to conjugate at the mutant sites): K44X, K55X, K64X, K83X, K84X, K90X, K102X, K105X, and K112X.
  • K34X, K43X, K62X, K63X, K69X, K81X, K84X, and K91X preferably K34X, K43X, K62X, K63X, K69X, K81X, K84X, and K91X.
  • rCTB family proteins GI: 229616 preferably K43X, K63X, K69X, K81 , K84X. and K91 X.
  • rCTB family protein GI: 2781 121 preferably K35X, K44X, K62X, K69X, K81 X. K84X, and K91X.
  • rCTB family protein GL1421525 preferably K43X, K62X, K63X, K69X. K81X. K91X.
  • rCTB family B subunit proteins if they have a lysine at position 91 , most preferably K91X.
  • LTB and the LTB family proteins GF3062900, 1 169505, 1395122, 145833, 1648865,
  • X is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, K44X, K55X, K64X, K83X, K84X, K90X, K102X, and K105X.
  • LTB family protein 494265 preferably K34X, K43X, K62X, K63X, K69X, K81X, K84X. and K91X.
  • K91X is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites.
  • X is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, K47X, K48X, K89X, K100X, and K107X.
  • X is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, K48X, K76X, and K89X.
  • the invention further contemplates the addition of amino acid residues throughout the amino acid sequence of the rCTB family, the LTB family, Shiga toxin, Shiga-like toxin, and pertussis toxin to direct conjugation of various bioactive compounds such as immunogens, immunomodulators, or drugs to specified sites. Any residue can be mutated to introduce amino acid residues that promotes acceptable conjugation events. Hydrophobic coupling of rCTB
  • rCTB Although chemical coupling is an excellent way to produce Gm-1 targeted immunogens, it would be highly advantageous to alter rCTB in such a way that it no longer requires chemical coupling, but instead strongly binds to other proteins or immunogens non-covalently.
  • rCTB could be prenylated it would then display up to 5 hydrophobic isoprene tails per pentamer. It is expected that in the properly folded and assembled protein, these tails would be present on the surface of the protein in opposite orientation to the Gm- 1 binding surfaces.
  • the commonly occurring isoprene groups include farnesyl, geranyl, geranyl-geranyl; all other prenylation or hydrophobic modification are considered to achieve the same outcome.
  • Cholera toxin thus modified is expected to have an affinity for hydrophobic structures and surfaces.
  • Prenylated rCTB would bind to bacterial cell walls, cell membranes, virus membrane coats, and other hydrophobic structures such as hydrophobic proteins and hydrophobic phospholipids or adjuvants.
  • the isoprene groups on rCTB would spontaneously insert into any Iipid membrane, or hydrophobic miscelle, to non-covalently associate rCTB with the hydrophobic structure in such a manner as to present the ligand binding site of rCTB on the outer surface of the micelle.
  • This concept could be applied to making conjugates between rCTB and vaccine antigens or to promote ganglioside specificity in microsome or liposome delivery systems.
  • Prenylation naturally occurs on selected proteins in eukaryotic cells, such as GTP binding proteins.
  • C cysteine
  • A aliphatic amino acid
  • X any amino acid.
  • the isoprenyl group is attached to the cysteine via a thioether link and after modification the cysteine becomes the last amino acid in the sequence.
  • Other post-translational modifications such as modification of proteins with lipids, fatty acids, and glycosyl phospholipids also occur and could potentially serve the same purpose as prenylation.
  • the gene for cholera toxin B is modified to include a prenylation signal that would permit in vitro prenylation.
  • a prenylation signal that would permit in vitro prenylation.
  • This may include a C-terminal cysteine, C-terminal CAAX box sequence (SEQ ID NO: 34), or any other sequence necessary or sufficient to achieve in vitro or in vivo prenylation.
  • a plasmid containing the mutant cholera toxin B gene is transfected into a suitable host for expression.
  • a high expression rCTB vector is used to express the mutated rCTB in bacteria. Once the mutated rCTB has been expressed and purified, it is used as a substrate for in vitro prenylation.
  • prenylation is performed with the appropriate prenylation enzymes and substrates.
  • the prenylated rCTB product is purified as necessary and used to produce the desired conjugated product.
  • prenylation reactions permit, prenylation of rCTB is performed in the presence of the conjugation partner thus allowing immediate binding of the modified rCTB to the immunogen or vaccine. This may serve to stabilize prenylated rCTB or facilitate production and purification.
  • An alternative embodiment involves co-transfecting bacterial or eukaryotic cells to produce rCTB and the necessary proteins for prenylation.
  • both the rCTB and prenylation proteins may need to be targeted to the same compartment for efficient prenylation.
  • This could be the cytoplasm, periplasm, or extracellular milieu of bacterial, or the cytoplasm, any of the secretory compartments or other organelles in eukaryotic expression systems.
  • Confirmation of hydrophobic coupling, purification, and Gm-1 binding assays would be performed essentially the same as chemically coupled rCTB, with variations in buffer and pH.
  • Vaccination would also be performed in essentially the same way. Vaccines
  • Vaccines contemplated include influenza virus vaccines, both whole and split, because influenza virus acquires a membrane coat and is thus capable of binding prenyl-rCTB to the membrane coat.
  • the split virus vaccines commonly contain the membrane coat protein hemagglutinin. This protein binds to prenyl-rCTB through hydrophobic patches on its surface.
  • Another suitable vaccine is whole cell pertussis, where prenyl-CTB could insert the hydrophobic groups into the outer membrane of B. pertussis.
  • genetic fusion of rCTB with an immunogen Another option for production of an rCTB coupled immunogen is genetic fusion. Genetic fusion would occur using a vector that contains a promoter for expressing the fusion protein, the DNA sequence of the cholera toxin binding subunit rCTB, and an immunogenic peptide coding sequence. The rCTB and the immunogenic peptide coding sequence would be linked such that they were in the proper reading frame producing a fusion protein. The fusion protein would be expressed, secreted, and purified for use as a vaccine. rCTB fusion proteins are as shown in Table 2.
  • HIV epitope is flanked by Kpnl and Mscl restriction enzyme sites, allowing easy insertion of other coding sequences into CTB
  • Microorganisms which invade via mucosal membrane surfaces are the best targets for rCTB vaccines. However, it could be used for almost any type of vaccine. Examples of diseases and antigens that could be coupled to rCTB for production of a vaccine are listed below in Table 3. As mentioned above, larger, whole and killed cell vaccines or whole virus vaccines could be produced particularly using the hydrophobic coupling. Vaccines which couple the rCTB protein in some way to an immunogen of choice would be particularly useful for any type of disease which is targeted to mucosal surfaces.
  • Production of a specific vaccine involves the steps of 1 ) identifying an antigen or immunogen; 2) coupling the antigen or immunogen to rCTB in some way (chemically, hydrophobically, or genetically); 3) isolating the coupled rCTB/immunogen and confirming that it still binds to Gm-1 ; 4) identifying that it works in vivo by injecting it into a mouse or other model animal; and 5) testing it for efficacy in humans or other primates. Examples of vaccine targets are shown in Table 3 with potential antigens. TABLE 3: HUMAN INFECTIOUS DISEASES AND VACCINE ANTIGENS
  • CTB-autoantigen conjugates Autoantigen specific peripheral T cell tolerance is induced by CTB-autoantigen conjugates.
  • Peripheral tolerance suppresses auto inflammatory disease by down regulating Thl .
  • CTB-autoantigens can even reverse existing inflammatory cell proliferation in animals.
  • Autoimmune diseases considered for treatment using CTB include without limitation: rheumatoid arthritis, encephalomyelitis (or other neuron demyelinating diseases), diabetes, and female anti- paternal immuno-contraception. Reversal of inflammatory cell proliferation (thl tolerization) was shown in autoimmune models for diabetes in NOD mice (insulin-CTB conjugates; Bergerot et al. PNAS 1997 94:4610- 14.).
  • the rCTB of the invention can be chemically, hydrophobically, or genetically coupled to the above-mentioned antigens and fed to animal models to test the efficacy. It is believed that because such a treatment was effective in the above examples it will be as effective or more so using the advantageous rCTB of the invention. Additionally, the rCTB conjugates of the invention are easier to make, more likely to work because the site of conjugation can be controlled, and yield a higher percentage of conjugated products that in turn will induce both a systemic and mucosal response. The rCTB or other B subunits of the invention can also be used to induce tolerance to infection.
  • tolerization may be induced by administering the Leshmania major produced immunodominant antigen LACK, which generates a CD4 + T cell dominant response and drives a th2 response to associated antigens. Th2 facilitates lesion development and leads to unresolved infection.
  • LACK+ transgenic mice are tolerant of LACK and resolve infection. LACK fed animals are tolerized and resolve infection. ( McSorley et al, Eur. J. Immunol. 1998, 28:424- 32.) showed that CTB-LACK, fed or given nasally, down regulated the T cell proliferative response to LACK and allowed animals to resolve (fight off) disease more effectively. Additionally, responses to diseases associated with the development of acute autoimmunity such as Reiter's syndrome or Lyme disease can be treated with tolerizing conjugates.
  • the expression plasmid MS-0 (see Figure 2) was used to express rCTB and variants.
  • MS-0 containing the rCTB gene is named pML-CTBtacl .
  • the plasmid pML-CTBtacl surprisingly generates up to five times the product which was generated by a comparable plasmid (SBL's vector pJS162).
  • PML-CTBtacl was constructed by cloning a portion of the CTB genomic region and the complete CTB coding region into plasmid MS-0 creating a 3.66 Kb expression plasmid.
  • the PvuII site in the polyhnker was destroyed during cloning
  • the plasmid contains a tac promoter from pKK223, an EcoRI-BamHI polyhnker fragment, and can be found at genbank accession No M77749
  • the encoded protein is identical to the sequence fiom V cholera strain 569B (SEQ ID NO 2)
  • the signal sequence (SEQ ID NO 3) is also fiom the CTB V cholei a classic strain 569B CTB gene
  • the complete nucleotide sequence of V cholera strain 569B CTB gene is shown in Figure 1 (SEQ ID NO 1)
  • the signal sequence for LTB (SEQ ID NO 15) is MNKVKCYVLFTALLSSLCAYG and can be used in the production of mutants or variants of LTB Measurement of Expression Level of rCTB mutant or variant
  • concentration of all proteins tested is measured by comparison to a standard curve of rCTB at defined concentrations in the Gm- 1 ELISA
  • concentrations in the Gm- 1 ELISA are then used to determine the sample concentration which is then multiplied by the dilution factor to obtain the correct concentration of the unknown sample
  • Gm- 1 ELISA One limitation of the Gm- 1 ELISA is that it only identifies the relative binding concentrations of wild type vs mutant rCTB Thus, actual concentrations must be confirmed by A280 or by Lowry, Bradford, BCA or similar colorimetric protein assays known by those practiced
  • any mutation to the rCTB sequence might result in an increase or decrease in receptor binding affinity for Gm- 1 and other ligands (Backstrom et al 1997 Mol Microbiol 24 489-497, Merritt et al 1995 Structw e 3 561 -570) Any significant change in receptor affinity of a newly created mutant rCTB foi Gm- 1 may cause the loss of binding in a Gm- 1 ELISA and result an "apparent" decrease in concentration
  • each test protein is initially purified to homogeneity using methods discussed below From these, the purity is demonstrated by comassie or silver stained polyacrylamide gel electrophoresis, a technique well known in the art The relative concentration of each protein is determined by A280 and confirmed by protein concentration assays Equivalent concentrations of each protein sufficient to saturate the ganglioside moiety (e g ⁇ 50 ⁇ g/ml), are incubated in a Gm- 1 ELISA plate A two-fold serial dilution of each mutant or unlabele
  • a standard curve for each mutant can be generated and compared to a similar curve for unlabeled wild type (positive standard curve control). Discrepancies from the positive standard curve control reflect significant changes in the affinity of the mutant rCTB for gm-1. The difference between curves can be quantified to determine the quantitative differences in affinity assuming the wild type affinity of 4.6x10-12M. Purification of rCTB and rCTB variants
  • the bacteria expressing rCTB or mutants of rCTB were grown in a shaker flask.
  • the supernatant was clarified by centrifuging the cells at 7000 x g (avg.) for 15 min at 4°C into a pellet.
  • a step wise precipitation of protein with increasing concentrations of ammonium sultate results in highly purified rCTB product. Accordingly, ammonium sulfate was gradually added to the culture supernatant to bring the ammonium sulfate concentration up to 30% (vol/vol) while stirring at room temperature. After 1 hour of precipitation without stirring, the sample was centrifuged at 14,000 x g (avg.) for 15 minutes at 4°C.
  • the sample was then placed in dialysis tubing (7000 MWCO). If the sample is not immediately used, it can be stored undialyzed for up to one month at 4°C until ready to use. When dialysis was performed, one-liter volumes of buffer were used for at least one hour each, changing the buffer three times. Purification of rCTB by DEAE Ion-exchange Chromatography
  • This part of the protocol applies specifically to ammonium sulfate precipitated rCTB.
  • a DEAE Sepharose Fast Flow gel of choice was packed on an Amersham Pharmacia Biotech column following the manufacturer's directions. 15 ml of a well-mixed gel slurry produced about 10 ml bed volume. The flow rate for packing was at least 4 ml/min.
  • a flow rate adapter was used with the column. The column was washed with 1 M NaCl to activate the column bed, or 2 M NaCl to regenerate a spent column bed.
  • the flow rate for all washes did not exceed 75% of the packing rate, or 3 ml/min.
  • the column was extensively equilibrated with Buffer A (10 mM Sodium Phosphate Buffer, pH 7.5) to remove all salt.
  • the sample containing rCTB was applied at a rate of 1 - 1.5 ml/min. Each fractions was tested for the presence of rCTB.
  • the column was washed with Buffer A at a flow rate of 3 ml/min until the optical density at A280 dropped below 0.02, confirming the removal of all non-specific and cationic species.
  • the column was washed with Buffer A containing 50 mM NaCl, until the optical density at A280 dropped below 0.02.
  • RCTB was eluted from the column with Buffer A containing 100 mM NaCl. All fractions were collected and pooled. Approximately 80% of the total column bound rCTB was recovered in these fractions. The column was washed with Buffer A containing 1 M NaCl until the optical density at A280 dropped below 0.02. Before regeneration of the column, the DEAE bed was washed with 10 mM sodium phosphate, pH 7.5 to remove all of the salt. Alternatively, CTB bound to the DEAE column can be eluted with a salt gradient from 0.02M NaCl to 1 M NaCl in buffer A. Fractions containing rCTB are pooled, dialyzed or concentrated in the buffer of choice.
  • the Ganglioside-Affigel columns were produced using Affigel (Pierce, Rockford, IL).
  • the smaller Ganglioside-Affigel column (0.5 ml bed volume) had the capacity to bind 1-2 mg of rCTB, while the larger (5 ml bed volume) will bind at least 7 mg.
  • the following buffers were used: 0.1 M Na-phosphate buffer, pH 7.5; 0.1 M Na-phosphate buffer, pH 7.5, 0.5 M Na CI; 5 M guanidine thiocyanite in DI water, freshly made in a 50 ml conical tube.
  • the culture supernatant was centrifuged at 10,000 rpm for 10 min (SS-34). Particulate matter was avoided as it clogs the column.
  • the column was equilibrated with 0.1 M Na-phosphate buffer, pH (2-5 column volumes). The sample containing rCTB was added and the flow through was collected and applied once more to allow quantitative binding to the column.
  • the column was washed with 0.1 M Na-phosphate buffer, pH 7.5 until the A280 was close to 0, the column was washed again with 0.1 M Na-phosphate buffer, pH 7.5, 0.5 M NaCl until the A280 was close to 0.
  • the column was equilibrated with 0.1 M Na-phosphate buffer, pH 7.5 (2 column volumes).
  • Fresh guanidine thiocyanite solution was prepared in 1 ml steps, 1 ml fractions were collected. The column was allowed to sit for 10 min after addition of the first two 1 ml additions of the elution buffer to the column. This ensured complete elution of rCTB from the ganglioside resin.
  • the A280 containing fractions were pooled and dialyzed against 500 ml of 0.1 M Na-phosphate buffer, pH 7.4, with no stirring. A total of 4 buffer changes were performed with the last two in the desired buffer in which to store the protein.
  • rCtB can be purified by cation exchange on a CM Sepharose Fast Flow ion exchange column. Briefly, NH4SO4 salt precipitated or DEAE eluted rCTB can be dialyzed against 20 mM Tris-HCI, 10 mM NaCl, pH 8.4 and the dialysate applied to the column.
  • rCtB product After washing, a highly purified rCtB product can be eluted with a continuous salt gradient of 10 mM to 300 mM NaCl in 20 mM Tris-HCI, pH 8.4.
  • EXAMPLE 2 Mutagenesis of rCTB Mutagenesis was initially performed by oligonucleotide-directed in vitro mutagenesis according to Kunkel, TA, Roberts, J., and Zakour, R. "Rapid and efficient site-specific mutagenesis without phenotypic selection", Methods Enzymol, 154, 367-382, 1987. Subsequently mutagenesis was performed essentially according to Nelson, M. and McClelland, M., Methods Enzymol. 216, 279-303, 1992. The results of the mutagenesis were confirmed by DNA sequencing.
  • a lysine residue is inserted into the rCTB sequence of SEQ ID NO 2 to replace amino acid Asn 103. Asparagine's polarity comes from an amino side chain which is uncharged at neutral pH. Replacement of Asn 103 with a lysine may prove to be an effective and novel conjugation site.
  • a lysine residue is inserted into the rCTB sequence of SEQ ID NO 2 to replace the amino-terminal amino acid Ala 102.
  • a lysine residue is inserted at position Alal .
  • a lysine residue is inserted at position Pro2. Although this mutant changes the structure of the amino terminus, Gm-1 binding affinity and antigenicity of the resulting composition is not compromised by the mutation.
  • Amino acids 14-20 form a ⁇ -sheet on the outer surface of rCTB with many of the side chains facing outward. Of the amino acid residues that form this structure, His 18, is particularly suitable for mutagenesis. Accordingly, a mutant rCTB protein is generated having the mutation H18K. Substitution of His 13 for any other amino acid may effect Zn + 2 binding characterisitics of rCTB as well as pentamer-pentamer self association. Elimination of either of these characteristics might be desired for purposes of biochemical isolation of the mutant proteins.
  • Immunogenicity is determined by injection of the rCTB:Immunogen into balb/c mice. 1:1,
  • Mutant CTB proteins CTB K91G and CTB-K62G, 63G, 91 G were modified, expressed, and purified using the method described in Examples 1-2. Mutation of K91 was chosen as a site for substitution because of its proximity to the Gm-1 binding site of CTB and it known interaction with the terminal glactose of Gm-1. Further, as discussed above, K91 is highly reactive with small molecular conjugates, such as FITC or SPDP. Accordingly, conjugations with heterobifunctional reagents are likely to create molecular complexes with diminished Gm-1 binding affinities, some important modifications to protocols which create a simpler, more efficient coupling reaction with SPDP.
  • the pH of the conjugation must be > 8.0, and the SPDP (N-Succinimidyl 3-[2- pyridyldithio]propionate) modified rCTB and its associated molecule must be highly concentrated.
  • rCTB wild type was successfully coupled to bovine serum albumin (BSA) and to Diphtheria toxoid (Dt).
  • BSA bovine serum albumin
  • Dt Diphtheria toxoid
  • neither BSA nor Dt was SPDP modified prior to conjugation.
  • Borate-Phosphate buffers a 10X stock solution (2L) was made by adding 12.4 g. Boric acid, 175.3 g NaCl, and 136.09 g Potassium phosphate (monobasic) into 1.5 liters of water. The solution was adjusted to a pH of 6.6 with 5M KOH and then brought up to a final volume of 2 liters with water. The solution was filtered through 0.2 micron filter. The pH of a I X solution was 7.0. Borate-Phosphate Buffer, pH 8.5 was IX buffer adjusted with 5M KOH.
  • the rCTB was modified using ten-fold molar excess of SPDP over rCTB.
  • the SPDP was weighed and diluted to 5 mg/ml using anhydrous N,N ⁇ dirnethylformamide (DMF), containing the molecular sieves (Grade 562, Type 3a, 4-8 mesh beads. Fisher Scientific, Tustin, CA).
  • DMF N,N ⁇ dirnethylformamide
  • the SPDP and rCTB were incubated and allowed to react for at least 1 hour at room temperature. Excess SPDP was removed by running a G-25 gel filtration column (1.5 cm x 9 cm bed volume is the minimum required to separate excess SPDP).
  • SPDP modified rCTB 10 mM sodium phosphate buffer, pH 7.5 containing 50 mM NaCl was used for column running buffer.
  • the SPDP modified rCTB was concentrated by using Amicon centricon c-30 (30 kD cut-off) to a volume between 1-2 ml. Conjugation of protein to SPDP modified rCTB Unmodified protein (the immunogen - i.e. BSA or Dt) was dialyzed against 3 x 1000 volumes Borate-Phosphate buffer, pH 7.0. SPDP modified rCTB and unmodified protein (immunogen) were combined at selected molar ratios and incubated overnight. The next the sample was concentrated using a Centricon 30 (30,000 MWCO Millipore, Bedford, MA).
  • CTB proteins CTB-H18C and CTB-M101C were modified, expressed, and purified using the methods described in Examples 1 -2.
  • the rCTB proteins were treated with 100 mM DTT for 2 hours at room temperature. DTT was removed by centrifugation for 2 min at 2000g through a 1 ml spin column packed with Biogel P6 polyacrylamide gel (BioRad, Cambridge, MA), equilibrated with 25 mM sodium phosphate buffer pH 7.0/10 mM ethylenediaminetetraacetic acid (EDTA). The collected fraction was incubated for 2 hours at room temperature with maleimide-activated immunogen (i.e. immunogen functionalized with the cross-linker SMCC, Sigma).
  • maleimide-activated immunogen i.e. immunogen functionalized with the cross-linker SMCC, Sigma.
  • ELISA conjugates of Immunogen and rCTB were incubated with GLMl -coated microtitre plates and immobilized Immunogen was detected with the chromogenic substrate 3,3',5,5' tetramethylbenzidine (TMB, KPL). Detection of plate bound immunogen which was dependent on a coating of GM-1 was interpreted as evidence that rCTB was physically linked to the Immunogen.
  • TMB 3,3',5,5' tetramethylbenzidine
  • rCTB was detected with polyclonal anti-rCTB sera, followed by goat anti-mouse Ig- alkaline phosphatase (A)(Amersham, Buckinghamshire, UK) and AP-specific substrate (BCIP/NBT, BioRad, Cambridge, MA). Immunogen was detected with antibodies specific to the immunogen, goat anti-mouse Ig-AP and BCIP/NBT.
  • Conjugates were purified by size exclusion chromatography based on the expected size of the conjugate. Additional purification was performed within a GM-1 or ganglioside affinity column to eliminate nonconjugated immunogen and within an antigen or immunogen specific column to eliminate residual free rCTB and rCTB-rCTB conjugates, respectively. This left only the bioactive conjugates which were assessed by SDS-PAGE and ELISA as described in Example 6.
  • ganglioside affinity by the GM-1 binding sites in mutant CTB, wild type CTB, or conjugates derived therefrom can be assayed by ELISA analysis.
  • the monosialoganglioside, GM-1 was used at a concentration of 0.3 nmol/ml PBS.
  • One hundred microliters of ganglioside solution was added to each well of a 96 well microtiter plate and incubated overnight at 22°C. The following day, the plate was washed twice with PBS utilizing a Bioplate Autowasher EL-404 (Bio-Tec Instruments, Winooski, VT).
  • All wells of the plate were then coated with 200 ⁇ l of a 0.1 % BSA in PBS solution for 30 minutes at 37°C. The plate was washed three times in PBS containing 0.05% tween-20 and evacuated of remaining solution. All wells, other than the initial test wells, received 100 ⁇ l of a solution of 0.1 % BSA, 0.05% tween-20 in PBS. Test wells then received 150 ⁇ l of 15 ⁇ g CTB/ml test mutant, wild type, or conjugate. A three-fold serial dilution was then conducted across the plate, sequentially transferring and diluting 50 ⁇ l from the second test well into 100 ⁇ l buffer in the third well and so on for up to twelve dilutions.
  • the plate was incubated for 90 minutes at 22°C. The plate was then washed three times as described above. All wells then received either 100 ⁇ l of a 1/20,000 dilution of mouse anti-rCTB antiserum or a pre-determined dilution of mouse anti-serum to the coupled compound. Wells were incubated one hour at 22°C and subsequently washed three times as above. Test wells then received 100 ⁇ l of a 1/3000 dilution of horseradish peroxidase conjugated goat anti-mouse IgG and were allowed to incubate one hour at 22°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention porte sur une protéine de recombinaison de la sous-unité B de AB5 comprenant au moins une mutation. Cette mutation modifie la quantité des restes d'acides aminés disponibles pour la modification chimique en comparaison avec une protéine de la sous-unité B de AB5 de génotype sauvage. Cette protéine de recombinaison conserve une affinité de liaison efficace du ligand cible. Par exemple, des mutations de détermination spécifique sont produites dans la sous-unité B de la toxine du choléra (CTB) de sorte qu'elle puisse toujours se lier avec une haute affinité à son récepteur, Gm-1, mais puisse être liée de manière covalente et spécifique au niveau des lysines ou cystéines à un immunogène ou vaccin. Le vaccin obtenu à partir de cette liaison est un vaccin contre l'infection des muqueuses qui a une immunogénicité élevée du fait de son interaction avec la CTB. Ce vaccin peut être produit facilement et à faible coût. En variante, l'invention porte également sur une technique de traitement de la CTB de sorte qu'il n'y ait pas de fixation par liaison non covalente avec un vaccin ou un immunogène.
EP00968795A 1999-10-08 2000-10-05 Mutants de la sous-unite b de la toxine ab 5? aux caracteristiques de conjugaison chimique modifiees Withdrawn EP1222202A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15856199P 1999-10-08 1999-10-08
US158561P 1999-10-08
PCT/US2000/027607 WO2001027144A2 (fr) 1999-10-08 2000-10-05 Mutants de la sous-unite b de la toxine ab5 aux caracteristiques de conjugaison chimique modifiees

Publications (1)

Publication Number Publication Date
EP1222202A2 true EP1222202A2 (fr) 2002-07-17

Family

ID=22568704

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00968795A Withdrawn EP1222202A2 (fr) 1999-10-08 2000-10-05 Mutants de la sous-unite b de la toxine ab 5? aux caracteristiques de conjugaison chimique modifiees

Country Status (7)

Country Link
EP (1) EP1222202A2 (fr)
JP (1) JP2003511061A (fr)
AU (1) AU7865900A (fr)
CA (1) CA2385172A1 (fr)
IL (1) IL149009A0 (fr)
NZ (1) NZ518342A (fr)
WO (1) WO2001027144A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115382D0 (en) 2001-06-22 2001-08-15 Univ Bristol Mutant
WO2003046560A2 (fr) 2001-11-30 2003-06-05 National Research Council Of Canada Nouvelles molécules d'auto-assemblage
WO2005030935A2 (fr) 2003-09-25 2005-04-07 The Research Foundation Of State University Of New York Activites adjuvantes de mutants de l'absence de l'enterotoxine lt-iia et lt-iib se liant au ganglioside
ATE521629T1 (de) 2005-10-07 2011-09-15 Angeletti P Ist Richerche Bio Matrixmetalloproteinase-11-impfstoff
KR101303282B1 (ko) 2010-11-08 2013-09-03 한국생명공학연구원 Ａｂ타입 세균 독소의 톡신 ｂ－서브유닛 결손에 의해 ａｂ타입 세균 외독소가 결여된 균주 및 이의 용도
IL286537B (en) 2013-03-15 2022-07-01 In3Bio Ltd Synthetic proteins that assemble themselves

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636842B1 (fr) * 1988-09-27 1994-06-10 Liege Universite Etat Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
JPH02115129A (ja) * 1988-10-21 1990-04-27 Kokuritsu Yobou Eisei Kenkyusho 抗ウィルス剤
US5834246A (en) * 1989-09-18 1998-11-10 Vitec Aktiebolag Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0127144A2 *

Also Published As

Publication number Publication date
WO2001027144A3 (fr) 2002-01-17
IL149009A0 (en) 2002-11-10
JP2003511061A (ja) 2003-03-25
AU7865900A (en) 2001-04-23
CA2385172A1 (fr) 2001-04-19
NZ518342A (en) 2004-04-30
WO2001027144A2 (fr) 2001-04-19

Similar Documents

Publication Publication Date Title
JP4840745B2 (ja) 熱ショックタンパク質とオリゴ糖または多糖とから形成されるコンジュゲート
JP3506431B2 (ja) ジフテリア毒素受容体結合領域
CA2190494C (fr) Composition de support d'immunogene de polypetide d'heterodimere et son procede d'utilisation
JPH11503617A (ja) 融合タンパク質としての異種抗原の発現系
US20050244425A1 (en) Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
JP2003534821A (ja) Ｔ細胞レセプター融合体および結合体ならびにそれらの使用方法
JP2002502363A (ja) 改変／キメラスーパー抗原およびその使用
JPH06509563A (ja) 炎症性関節炎の治療用の表皮細胞成長因子受容体を標的とする分子
JP4296536B2 (ja) Ｇｂ３レセプター発現細胞を標的とする分子の一般担体
JP4063879B2 (ja) 所望の決定基に対する免疫応答の誘導
JP2002525041A (ja) 連鎖球菌性Ｃβタンパク質組成物
JP2003530360A (ja) 薬剤送達のためのペプチド複合体
De Haan et al. Enhanced delivery of exogenous peptides into the class I antigen processing and presentation pathway
JP2001511122A (ja) 新規な上皮組織標的化薬剤
CZ20013709A3 (cs) Analog interleukinu 5, fragment nukleové kyseliny, vektor, buňka, přípravky a pouľití
Bäckström et al. Structural basis for differential receptor binding of cholera and Escherichia coli heat‐labile toxins: influence of heterologous amino acid substitutions in the cholera B‐subunit
EP1222202A2 (fr) Mutants de la sous-unite b de la toxine ab 5? aux caracteristiques de conjugaison chimique modifiees
CA2069106A1 (fr) Proteines chimeriques
US6825318B2 (en) Mimetic peptides for an epitope of apolipoprotein B-100, concatemers of the peptides, and modified peptides, and compositions comprising the same
JP4820000B2 (ja) 免疫処置のためのベロ毒素ｂサブユニット
EP0368819A1 (fr) Expression de la sous-unité liante de la toxine chloérique à l'aide de promoteurs étrangers et/ou de séquences guides
CA2182682A1 (fr) Molecules immuno-interactives i
JP2001503981A (ja) 粘膜ワクチン送達システムとしての分泌性イムノグロブリンａ
EP2672982B1 (fr) Immunoconjugués d'haptène polypeptidique mimétique de ghreline ayant une solubilité et une immunogénéicité améliorées et leurs procédés d'utilisation
AU2007200834B2 (en) Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020506

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: POWDERJECT PHARMACEUTICALS PLC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SBL VACCIN AB

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060503